E

veryone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown — of individuals, companies, what have you — that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.

Winners:

Novo Nordisk scored a modest publicity coup by very publicly committing to limiting price hikes on its medicines to single-digit increases annually. The company is now the second big drug maker to do so, after Allergan. And while many people may not have read his note, Novo president Jakob Riis carefully and calmly used the opportunity to skewer pharmacy benefit managers and insurers, which the pharmaceutical industry is increasingly blaming for the rising cost of medicines.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy